Search results for "modality."

showing 10 items of 631 documents

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial

2015

KRAS mutation has been reported as a marker of radio-resistance in rectal cancer and unfavourable outcome in both colon and rectal cancer. This study suggests that a single-nucleotide polymorphism of the KRAS gene (LCS-6 variant) may predict response to neoadjuvant treatment and mitigate the poor prognosis associated with KRAS mutation in locally advanced rectal cancer.

MaleOncologyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLET-7 MICRORNA-BINDINGCetuximabmedicine.disease_causeCOLORECTAL-CANCER3'-UNTRANSLATED REGION0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsRectal cancerNeoadjuvant therapySingle-nucleotide polymorphism0303 health sciencesCetuximabCOLON-CANCERHazard ratioCAPOX RegimenChemoradiotherapyHematologysingle-nucleotide polymorphismMiddle AgedCombined Modality TherapyNeoadjuvant TherapyBINDING SITE POLYMORPHISM3. Good healthOxaliplatinLet-7Oncology030220 oncology & carcinogenesis5-FLUOROURACIL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleKRASLife Sciences & Biomedicinemedicine.drugAdultGenetic Markersmedicine.medical_specialtyGenotypeLCS-6 KRAS variantPolymorphism Single NucleotideDisease-Free SurvivalCLINICAL-TRIALProto-Oncogene Proteins p21(ras)03 medical and health sciencesSDG 3 - Good Health and Well-beinglet-7Internal medicineGastrointestinal TumorsBiomarkers TumorKRASmedicineHumansOncology & CarcinogenesisProgression-free survivalrectal cancerneoplasmsCapecitabineAged030304 developmental biologyCancer och onkologiScience & TechnologyRectal Neoplasmsbusiness.industryOriginal Articlesmedicine.diseasedigestive system diseasesMicroRNAsCancer and Oncologybusiness1112 Oncology And CarcinogenesisChemoradiotherapyRASAnnals of Oncology
researchProduct

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

2020

On behalf of the PETHEMA/GEM Cooperative Group.

MaleOncologyPhysics::Instrumentation and Detectorsmedicine.medical_treatmentKaplan-Meier EstimateHematopoietic stem cell transplantationBiochemistryhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentProspective StudiesComputer Science::Operating SystemsIn Situ Hybridization FluorescenceMultiple myelomaRandomized Controlled Trials as TopicComputer Science::Cryptography and SecurityHazard ratioHematopoietic Stem Cell TransplantationHigh-Throughput Nucleotide SequencingHematologyMiddle AgedFlow CytometryPrognosisCombined Modality TherapyProgression-Free Survivalmedicine.anatomical_structureFemaleClonal HematopoiesisMultiple Myelomamedicine.medical_specialtyImmunologyTransplantation AutologousInternal medicinemedicineHumansClinical significanceProgression-free survivalComputer Science::Distributed Parallel and Cluster ComputingAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryCell Biologymedicine.diseaseTransplantationClinical Trials Phase III as TopicMyelodysplastic SyndromesMutationBone marrowbusinessMonoclonal gammopathy of undetermined significance
researchProduct

Antiandrogens alone or in combination for treatment of prostate cancer: The European experience

1989

Abstract In Europe, antiandrogens have been used for many years to treat prostate cancer, either as monotherapy or as part of a “combination therapy” with either surgical or chemical castration. However, considerable debate still exists regarding the relative benefits of combination therapy versus antiandrogen monotherapy or castration alone. This article reviews the European experience with antiandrogen therapy, including the personal experiences of the authors.

MaleOncologymedicine.medical_specialtyCombination therapyAntiandrogensmedicine.drug_classUrologyurologic and male genital diseasesAntiandrogenchemistry.chemical_compoundProstate cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAntiandrogen TherapyChemical castrationRandomized Controlled Trials as TopicGynecologybusiness.industryProstatic NeoplasmsAndrogen Antagonistsmedicine.diseaseCombined Modality TherapyFlutamideEuropeCastrationchemistrybusinessOrchiectomyhormones hormone substitutes and hormone antagonistsUrology
researchProduct

Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Anal cancer is strongly associated with human papilloma virus (HPV) infection. Using polymerase chain reaction (PCR), the presence of the HPV genome has been identified in 80%–85% of cases. Other important risk factors include human immunodeficiency virus (HIV), immune suppression in transplant recipients and cigarette smoking. Herpes simplex virus (HSV)may play a secondary role in disease progression.Dietaryhabits, chronic inflammatory diseases and the presence of haemorrhoids do not appear to predispose to epidermoid anal cancer. Previous (gynaecological, lymphoma or leukemia) or subsequent (e.g. lung, bladder, vulva, vagina or breast) malignancy is more likely in anal cancer patients. Th…

MaleOncologymedicine.medical_specialtyPalliative careAnal CarcinomaDiseaseMalignancyGastroenterologyMeta-Analysis as TopicRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineGenetic predispositionHumansAnal cancerNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicSalvage TherapyRadiotherapybusiness.industryIncidencePalliative CareHPV infectionCancerHematologyAnus Neoplasmsmedicine.diseaseCombined Modality TherapyEuropeTreatment OutcomeOncologyFemalebusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Phase 2 Trial of the Continuous IV Administration of Interferon-? in Patients With Disseminated Malignant Melanoma

2006

BACKGROUND Interferons have been reported to significantly contribute to tumor suppression via both induction of p53 gene expression and inhibition of angiogenesis. OBJECTIVE The assessment of treatment toxicity and antitumoral effectiveness of continuous IV administration of interferon-beta based on an overall evaluation of laboratory, radiographic, and clinical parameters observed during the trial. METHODS The authors treated patients with advanced malignant melanoma with continuous IV infusions of 1 x 10(6) IU interferon-beta daily ( approximately 0.6 x 10(6) IU interferon-beta/m2 daily). RESULTS Continuous IV administration of interferon-beta had no significant effect on overall patient…

MaleOncologymedicine.medical_specialtySkin NeoplasmsAngiogenesisAntineoplastic AgentsDrug Administration ScheduleInterferonInternal medicinemedicineHumansIn patientNeoplasm MetastasisInfusions IntravenousMelanomaAgedInterferon betabusiness.industryMelanomaInterferon-betaGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyDiscontinuationSurgeryTreatment OutcomeToxicityFemalebusinessmedicine.drugSKINmed
researchProduct

High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late, rectal toxicity

2017

PURPOSE: To determine the significance of dose-volume histogram parameters for predicting late rectal toxicity (LRT) after single-fraction high-dose-rate brachytherapy (HDRBT) boost and external beam radiotherapy (EBRT) in prostate cancer. MATERIALS AND METHODS: Three hundred patients with intermediate- or high-risk prostate cancer were included between August 2010 and March 2015. Treatment comprised a single-fraction HDRBT boost of 15.0 Gy plus EBRT (46.0 Gy delivered in 23 fractions) or an HDRBT boost of 9.5 Gy plus EBRT (60.0 Gy delivered in 30 fractions) if the seminal vesicles were infiltrated using real-time transrectal ultrasound-based planning. LRT was evaluated every 3 months after…

MaleOrgans at RiskDose-volume histogramTime Factorsmedicine.medical_treatmentBrachytherapyBrachytherapyRectumLate rectal toxicity030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancerOrgan at risk0302 clinical medicinemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesExternal beam radiotherapyRadiation InjuriesAgedAged 80 and overProstate cancerbusiness.industryRadiotherapy Planning Computer-AssistedBiologically equivalent doseRectumProstatic NeoplasmsCommon Terminology Criteria for Adverse EventsMiddle Agedmedicine.diseaseCombined Modality TherapyHigh-Dose Rate BrachytherapyHigh-dose-rate brachytherapy boostRadiation therapyDose-volume histogram parametermedicine.anatomical_structureOncology030220 oncology & carcinogenesisRegression AnalysisDose Fractionation RadiationNuclear medicinebusinessFollow-Up Studies
researchProduct

Differential impact of a multimodal versus pharmacological therapy on the core symptoms of Attention Deficit Hyperactivity Disorder in childhood

2015

Abstract The aim of this study was to analyze the relative and differential efficacy of a combined versus medical treatment to reduce the symptoms of ADHD children in the school and family environment. A total of 100 subjects participated: 20 children with ADHD, their 40 parents and their 40 teachers. Half of the subjects were assigned to the drug group and half to the combined (drug plus psychosocial, psychoeducational intervention with teachers and mothers/fathers). Results The group analyses indicated that both treatments were effective, without significant differences between them. Individualized clinical analyses indicated that higher percentages of improvement and normalization were o…

MaleParentsmedicine.medical_specialtyTrastorns per dèficit d'atenció amb hiperactivitat en els infantsPharmacological therapyeducation.educational_degreePsychological interventionPsychiatric rehabilitationPsychiatric RehabilitationAttention deficit disorder with hyperactivity in children03 medical and health sciences0302 clinical medicinemental disordersDevelopmental and Educational PsychologymedicineCombined Modality TherapyAttention deficit hyperactivity disorderHumans0501 psychology and cognitive sciencesPsychiatryeducationChildDifferential impactAttention-deficit-disordered childrenMethylphenidate05 social sciencesTeacher Trainingmedicine.diseaseCombined Modality TherapyClinical PsychologyTrastorns per dèficit d'atenció en els infantsAttention Deficit Disorder with HyperactivityMethylphenidateCentral Nervous System StimulantsFemaleSchool TeachersPsychologyPsychosocial030217 neurology & neurosurgery050104 developmental & child psychologymedicine.drug
researchProduct

Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone …

2003

Immunotherapy is a recognized treatment for allergic respiratory diseases.

MaleParietaria; Androstadienes; Skin; Double-Blind Method; Combined Modality Therapy; Humans; Asthma; Child; Desensitization Immunologic; Anti-Allergic Agents; Plant Proteins; Pollen; Rhinitis Allergic Seasonal; Allergens; Treatment Outcome; Administration Inhalation; Adolescent; Administration Sublingual; Male; FemaleParietaria pollenAdolescentAdministration Sublingualsublingual immunotherapylate skin responsechildrenDouble-Blind Methodchildren; early skin response; fluticasone; late skin response; Parietaria pollen; sublingual immunotherapy; visual analog scoreAdministration InhalationChildSkinAndrostadieneAllergenearly skin responsefluticasonePlant ProteinRhinitis Allergic SeasonalCombined Modality TherapyAsthmaAnti-Allergic Agentvisual analog scoreParietariaTreatment OutcomeDesensitization ImmunologicPollenFemaleHuman
researchProduct

Solitary Fibrous Tumor: Integration of Clinical, Morphologic, Immunohistochemical and Molecular Findings in Risk Stratification and Classification Ma…

2021

Although solitary fibrous tumors (SFTs) have an unpredictable evolution, some specific clinicopathologic factors have been associated with the final outcome. We retrieved clinical, pathological and molecular data of 97 patients with a histological diagnosis of SFT and Signal transducer and activator of transcription 6 (STAT6) positivity. We retrospectively studied the pathological factors predictive of recurrence/metastasis and compared them with the clinical outcome. A wide immunohistochemical study and molecular analysis to detect NAB2/STAT6 gene fusion, tumor protein-53 (TP53) and/or (telomerase reverse transcriptase) TERT promotor mutation were performed. The risk of metastasis was calc…

MalePathologymedicine.medical_specialtySolitary fibrous tumorQH301-705.5CD99CD34APAF-1Risk AssessmentArticleCatalysisMetastasisInorganic ChemistryBiomarkers TumormedicineHumanssolitary fibrous tumorTelomerase reverse transcriptaseBiology (General)risk stratification systemsPhysical and Theoretical ChemistryQD1-999Molecular BiologyPathological<i>p53</i> mutationSpectroscopyRetrospective StudiesSTAT6<i>HTER</i> mutationbusiness.industryOrganic ChemistrySoft tissueGeneral MedicineMiddle AgedPrognosismedicine.diseaseCombined Modality TherapyImmunohistochemistryp53 mutationComputer Science ApplicationsChemistryHTER mutationSolitary Fibrous TumorsImmunohistochemistryFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesInternational Journal of Molecular Sciences
researchProduct

Bcl-2 and Mn-SOD antisense oligodeoxynucleotides and a glutamine-enriched diet facilitate elimination of highly resistant B16 melanoma cells by tumor…

2005

Mitochondrial glutathione (mtGSH) depletion increases sensitivity of Bcl-2-overexpressing B16 melanoma (B16M)-F10 cells (high metastatic potential) to tumor necrosis factor-alpha (TNF-alpha)-induced oxidative stress and death in vitro. In vivo, mtGSH depletion in B16M-F10 cells was achieved by feeding mice (where the B16M-F10 grew as a solid tumor in the footpad) with an L-glutamine (L-Gln)-enriched diet, which promoted in the tumor cells an increase in glutaminase activity, accumulation of cytosolic L-glutamate, and competitive inhibition of GSH transport into mitochondria. L-Gln-adapted B16M-F10 cells, isolated using anti-Met-72 monoclonal antibodies and flow cytometry-coupled cell sortin…

MaleProgrammed cell deathgovernment.form_of_governmentGlutamineSOD2Antineoplastic AgentsSoft Tissue NeoplasmsMitochondrionBiologyBiochemistryGlutaminase activitySuperoxide dismutaseMiceAnimalsMolecular BiologyMelanomaAntisense therapySuperoxide DismutaseTumor Necrosis Factor-alphaCell BiologyGenetic TherapyOligonucleotides AntisenseMolecular biologyAnimal FeedCombined Modality TherapyGlutathioneMitochondriaMice Inbred C57BLDisease Models AnimalOxidative StressMitochondrial permeability transition poreProto-Oncogene Proteins c-bcl-2Drug Resistance Neoplasmgovernmentbiology.proteinTumor necrosis factor alphaNeoplasm TransplantationThe Journal of biological chemistry
researchProduct